evolocumab + atorvastatin

Evolocumab + atorvastatin is a **combination therapy** using two distinct lipid-lowering agents: evolocumab, a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), and atorvastatin, a small-molecule inhibitor of HMG-CoA reductase (statin) used to lower cholesterol. Evolocumab increases the number of LDL receptors on hepatocytes by preventing PCSK9-mediated degradation, thereby enhancing clearance of LDL cholesterol from the bloodstream. Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and upregulating LDL receptor expression. This combination has been shown to produce **greater reductions in LDL cholesterol and biomarkers of inflammation** than either agent alone, particularly in patients with atherosclerosis or those who require additional LDL-C lowering beyond what statins can provide. Both agents are primarily indicated for the treatment of hyperlipidemia and cardiovascular risk reduction in populations with or at risk for atherosclerotic cardiovascular disease[1][2][6].

Other names

evolocumab plus atorvastatinevolocumab and atorvastatin